Kinevant Study Site

A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis

Status: Recruiting

Location: Kinevant Study Site

Conditions: Kinevant Study Site


Birmingham, Alabama

Palo Alto, California

Valencia, California

Denver, Colorado

Gainesville, Florida

Augusta, Georgia

Chicago, Illinois

Iowa City, Iowa

Kansas City, Kansas

New Orleans, Louisiana

Baltimore, Maryland

Minneapolis, Minnesota

Rochester, Minnesota

Greenville, North Carolina

Cincinnati, Ohio

Cleveland, Ohio

Philadelphia, Pennsylvania

Pittsburgh, Pennsylvania

Charleston, South Carolina

Rock Hill, South Carolina

Dallas, Texas

Houston, Texas

Charlottesville, Virginia

Falls Church, Virginia

Contact Information:

Gary Barrera
[email protected]

Brief Summary:
This is a randomized, double-blind, placebo-controlled study with an open-label extension (OLE).
Detailed Description:

This is a randomized, double-blind, placebo-controlled study with an OLE.

Participants will be randomized to receive namilumab or placebo in the 26-week Double-blind Treatment Period of the study. Namilumab, or placebo, will be administered subcutaneously (SC) every 4 weeks through Week 22 after the initial dosing period.

All participants, who complete the 26-week Double-blind Treatment Period, may be eligible to participate in the 28-week OLE.

Further details are in the protocol.

Read more
Contact Us

Contact Us

(281) 713-2962
800 Rockmead Drive, Suite 155
Kingwood, TX 77339
[email protected]

Social Media


Help Us End Suffering and Sudden Death from Myocarditis!

Donate to the Myocarditis Foundation Today!